Related Experiment Video
Updated: Jun 16, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
PSMA-Targeted 2-Deoxyglucose-Based Dendrimer Nanomedicine for the Treatment of Prostate Cancer
Anu Rani1, Anunay James Pulukuri1, Jing Wei2
1Department of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington 99164, United States.
Abstract:
Prostate cancer (PC) is the fifth leading cause of cancer-related deaths among men worldwide. Prostate-specific membrane antigen (PSMA), a molecular target of PC, is clinically used for the treatment and diagnosis of PC using radioligand approaches. However, no PSMA-based chemotherapies have yet been approved by the FDA. Here, we present a novel therapeutic approach using PSMA-targeted 2-deoxyglucose-dendrimer (PSMA-2DG-D) for targeted delivery of a potent tyrosine kinase inhibitor, cabozantinib (Cabo), selectively to PC cells. PSMA-2DG-D demonstrates intracellular localization in PSMA (+) PC cells through PSMA-mediated internalization. This PSMA-specific targeting translates to enhanced efficacy of Cabo compared to the free drug when conjugated to PSMA-2DG-D. Furthermore, systemically administered fluorescently labeled PSMA-2DG-D-Cy5 specifically targets PSMA (+) tumors with minimal off-target accumulation in the PC3-PIP tumor xenograft mouse model. This demonstrates that the PSMA-2DG-D platform is a promising new delivery system for potent chemotherapeutics, where systemic side effects are a significant concern.
Insights
This study introduces a novel PSMA-targeted drug delivery system for prostate cancer (PC) therapy. The PSMA-2DG-D platform effectively delivers cabozantinib to PC cells, enhancing treatment efficacy and minimizing side effects.
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery
Background:
- Prostate cancer (PC) is a significant global health concern, necessitating advanced therapeutic strategies.
- Prostate-specific membrane antigen (PSMA) is a validated target for PC diagnosis and radioligand therapy, but not yet for chemotherapy.
- Current limitations in PSMA-based chemotherapy highlight the need for innovative drug delivery systems.
Purpose of the Study:
- To develop and evaluate a novel PSMA-targeted 2-deoxyglucose-dendrimer (PSMA-2DG-D) platform for selective delivery of cabozantinib (Cabo) to prostate cancer cells.
- To assess the efficacy and targeting specificity of the PSMA-2DG-D-Cabo conjugate in preclinical models.
- To establish PSMA-2DG-D as a promising platform for targeted delivery of potent chemotherapeutics.
Main Methods:
- Conjugation of cabozantinib to a 2-deoxyglucose-dendrimer targeting PSMA.
- In vitro assessment of PSMA-mediated cellular uptake and intracellular localization in PSMA-positive PC cells.
- In vivo evaluation of tumor targeting and efficacy using a PSMA-positive PC3-PIP tumor xenograft mouse model with fluorescently labeled PSMA-2DG-D-Cy5.
Main Results:
- PSMA-2DG-D demonstrated efficient intracellular localization in PSMA-positive PC cells via PSMA-mediated internalization.
- Cabozantinib conjugated to PSMA-2DG-D showed enhanced anti-cancer efficacy compared to the free drug.
- Systemic administration of fluorescently labeled PSMA-2DG-D-Cy5 specifically targeted PSMA-positive tumors with minimal off-target accumulation in vivo.
Conclusions:
- The PSMA-2DG-D platform facilitates targeted delivery of cabozantinib specifically to prostate cancer cells.
- This novel drug delivery system shows significant potential for improving the efficacy of chemotherapies for prostate cancer.
- PSMA-2DG-D offers a promising strategy to enhance therapeutic outcomes while mitigating systemic side effects in PC treatment.
